CVRX (CVRx Inc.) רווח נקי למניה ב-12 החודשים האחרונים
The breakthrough status of the Barostim system has secured high loyalty among cardiologists for CVRx, Inc. (CVRX), as evidenced by the 12-month earnings per share history, where the parameter stabilized at -1.98. Management is successfully deploying devices through FDA approvals, while the current expansion of neuromodulators requires capital expenditures despite maintaining positive cash flow dynamics.
%20%D7%A8%D7%95%D7%95%D7%97%20%D7%9C%D7%9E%D7%A0%D7%99%D7%94%20%D7%9C%D7%A9%D7%A0%D7%94%20%D7%9E%D7%AA%D7%92%D7%9C%D7%92%D7%9C%D7%AA&width=1200&height=400&colorIndex=0&v=mwbxec28.yq-7cu2wow&start=20220704&end=20261111&filename=GURU_Markets_-_CVRX_-_CVRx-Inc._-_Earnings-per-share-for-the-trailing-year "CVRX - רווח נקי למניה (EPS TTM) CVRx, Inc. בטווח 04.07.2022 - 11.11.2026 | 👁️GURU.Markets👁️")
CVRX (CVRx Inc.): פילוחים אנליטיים ודוחות לפי אינדיקטורים
Annual earnings per share measures the final efficiency of capital by distributing the aggregate financial result among all shareholders to assess the asset's real return. By analyzing the annual net income per share of CVRx, Inc. (CVRX) on GURU.Markets, an investor can compare the profitability of CVRx, Inc. (CVRX) with its competitors, taking into account the impact of contract electronics manufacturing costs and external clinical trial management on the final profit profile.
